The Cash Cow in 'Fertility' Medicine
By Pamela M Tsigdinos,
Healthcare in America
| 10. 23. 2016
On average, the cost of a basic IVF cycle in the U.S ranges from $12,000 — $15,000 yet three out of four times it fails
20 million fails. This is one stat not discussed at the latest American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. It’s also not posted on fertility clinic member websites nor shared on their social media feeds but it should be.
Last week thousands of physicians, nurses, scientists and lab technicians gathered in Salt Lake City joined by legions of pharmaceutical representatives, ‘fertility’ entrepreneurs and service providers in full on ‘sell mode.’
It’s been nearly 40 years since in vitro fertilization (IVF) became available. There has been explosive growth in the size and scope of clinics and profit taking but no commensurate improvement in IVF outcomes.
Here are five other facts that aren’t widely known but should be:
Fact #1: ‘Fertility’ is now a huge market. That’s right: a market. The global In-Vitro Fertilization (IVF) market size was valued at $9.6 billion in 2014. A more recent report by Grand View Research, Inc. projects the global ... see more
Related Articles
By Pam Belluck, New York Times | 07.14.2021
The Cleveland Clinic Miller Family Pavilion
HealthMonitor, CC BY-SA 4.0,
via Wikimedia Commons
In a striking reflection of concern over the approval of the controversial new Alzheimer’s drug Aduhelm, two major American health systems have decided that they...
By Justin Jouvenal, Boston Globe | 07.13.2021
The Exxon clerk never got a good look at the assailants who robbed him at gunpoint in Fairfax County, so investigators hoped to bolster their case with the smallest of clues: the minuscule number of skin cells one perpetrator left...
By Shannon Brownlee and Jeanne Lenzer, Washington Monthly | 07.10.2021
Between 2010 and 2015, drug companies submitted data to the U.S. Food and Drug Administration (FDA) for three different drugs for Alzheimer’s disease, a devastating condition that afflicts six million Americans. The FDA rejected all three because the manufacturers ...
By Sabrina Imbler, New York Times | 06.29.2021
When Krystal Tsosie introduces her genomics students to the concept of biocommercialism — the extraction of biological resources from Indigenous communities without benefit — she always uses the same example: the Human Genome Diversity Project.
The researchers who conceived of...
